Epizyme, Inc. (EPZM) saw its loss widen to $35.02 million, or $0.60 a share for the quarter ended Dec. 31, 2016. In the previous year period, the company reported a loss of $22.23 million, or $0.53 a share. Revenue during the quarter dropped 13.87 percent to $0.48 million from $0.56 million in the previous year period.
Operating loss for the quarter was $35.48 million, compared with an operating loss of $22.28 million in the previous year period.
"2016 was a year of tremendous progress across all aspects of Epizyme, which set the stage for 2017 to be a transformational year for the company," said Robert Bazemore, president and chief executive officer of Epizyme. "We have a broad clinical development program with tazemetostat in multiple tumor types and treatment settings. We plan to present data from both our ongoing, global Phase 2 studies in both molecularly defined solid tumors and non-Hodgkin lymphoma in June, and to initiate discussions with regulators to define registration pathways for tazemetostat. We are advancing our ongoing monotherapy and combination studies and plan to announce the next development candidate from our preclinical pipeline this year. As we look ahead, we are on our way to achieving our vision of rewriting cancer treatment through novel epigenetic medicines."
Disclaimer: Please note that this is an auto-generated article. IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website. For queries contact: [email protected]
